Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation

Abstract In non‐small cell lung cancer (NSCLC), uncommon epidermal growth factor receptor (EGFR) mutations are mutations other than Ex19 deletion and Ex21 L858R, which are common mutations highly sensitive to EGFR‐tyrosine kinase inhibitors. Afatinib, a second‐generation EGFR‐tyrosine kinase inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayako Morita, Shinobu Hosokawa, Kotaro Yamada, Takahiro Umeno, Hirohisa Kano, Hiroe Kayatani, Masaaki Shiojiri, Makoto Sakugawa, Akihiro Bessho
Formato: Artículo
Lenguaje:English
Publicado: Wiley 2021-04-01
Colección:Thoracic Cancer
Materias:
afatinib
dacomitinib
EGFR‐TKI re‐administration
non‐small cell lung cancer
uncommon EGFR mutation
Acceso en línea:https://doi.org/10.1111/1759-7714.13897

Internet

https://doi.org/10.1111/1759-7714.13897

Ejemplares similares